30/09/2019
Marie Skłodowska-Curie Actions

15 PhD positions in Marie Sklodowska Curie ITN "A Nanovaccine Approach for the Treatment of Pancreatic Cancer" (PAVE)


  • ORGANISATION/COMPANY
    Percuros B.V.
  • RESEARCH FIELD
    Biological sciencesBiology
    ChemistryMolecular chemistry
    Medical sciencesOther
    PhysicsBiophysics
    PhysicsOptics
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    30/09/2020 17:00 - Europe/Brussels
  • LOCATION
    Multiple locations, see work locations below.
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    ca. 40
  • OFFER STARTING DATE
    01/10/2019
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • MARIE CURIE GRANT AGREEMENT NUMBER
    861190

 

15 PhD Positions

 

are available within the

 

Marie Skłodowska Curie Innovative Training Network on

 

A Nanovaccine Approach for the Treatment of Pancreatic Cancer - PAVE 

 

PAVE (www.pave-cancer.eu) is a Marie Skłodowska Curie Innovative Training Network funded by the European Commission. We are an established team of 10 academic and 3 industrial partner organizations from 7 European countries specialized on nanovaccines, immunotherapy, personalized nanomedicine approaches, image guided surgery, molecular imaging.

A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in men and women and still fatal in over 90% of patients. It is characterised by its extremely aggressive nature where it is also responsible for the highest mortality rate compared to other major cancers, resulting in excess of 250,000 deaths worldwide per annum. Current state-of-art therapies for advanced PDAC including chemo- and/or radiotherapy, despite extensive efforts, have met with only limited success.

Surgery is only applicable for those with early stages of the disease, or to relieve symptoms, if the cancer is blocking the bileduct or the bowel. There are two major reasons for the resistance of PDAC to conventional therapy. Firstly, PDAC has a very defining hallmark, where an abundance of stromal content is present in the tumour microenvironment (TME) to form a physical and biochemical barrier. Secondly, during progression of the disease, the body's immune system is hijacked to support the proliferation of the cancer. New approaches, such as immunotherapy, are therefore needed where it has already shown promise in overcoming many aspects of this resistance. Immunotherapy has the potential to treat minimal residual disease after pancreatic resection (surgery) as well as for metastatic and non-resectable PDAC. Our objective for this project is to bring together a multidisciplinary and intersectoral group to develop novel vaccine approaches, including use of multiple immunomodulating components.

We will provide a structured 3-years cutting-edge PhD training programme in and beyond the fields of cancer and its biological basis, immunotherapy, medical physics, optical physics, diagnostic tools (e.g. genetic, molecular diagnostic) and nanotechnology.

The selection process has already started in October, so we invite all candidates to send your application as soon as possible. We intend to recruit all ESRs by September 2020. 

We are looking for highly motivated and talented PhD students holding a Master's degree or Bachelor's degree (UK) in scientific fields like biology or chemestry. Excellent command of spoken and written English, communication skills as well as team spirit are essential. We are offering a competitive, interdisciplinary environment with a track record of intense mutual collaboration. In addition to the individual training-through-research our programme includes further elements such as workshops, summer schools, internships and secondments to the partners’ laboratories.

The following eligibility rules apply for participation in a Marie Skłodowska Curie Innovative Training Network:

Applicants must be in the first 4 years after obtaining their Master´s degree and must  not  have  resided  or  carried  out  their  main  activity (work, studies,  etc.) in the host country for more than 12 months in the 3 years immediately before the recruitment date. In addition, local regulations of the host countries may apply. The salary is based on standard living, mobility and family allowances which are adapted to the respective country of recruitment.

 

The following positions are available:

 

NOT AVAILABLE ANYMORE Max-Planck Institute of Experimental Medicine, Germany

Principal Investigator - Prof. Frauke Alves

ESR 1 - Identification of cell-cell interaction and biological processes in the tumour environment of biological samples before/after intervention by high resolution 3D optical imaging technologies.

 

Erasmus Medical Centre, The Netherlands

PI - Laura Mezzanotte

ESR 2 - Study of PDAC carcinogenesis using novel fluorescence and bioluminescence tools

 

RCI Regensburg Center for Interventional Immunology, Germany

PI - Philip Beckhove

ESR 3 - Improving PDAC vaccination by targeting T cells against PDAC associated immunogenic antigens in combination with pharmacological inhibition of PDAC intrinsic pathways of immune resistance

 

University of Barcelona, Spain

PI - Joan Carles Domingo Pedrol

ESR 4 - High-throughput solid-phase synthesis and the construction of chemical antigens using different topologies and development of supra-platforms for the construction of “Signals Conjugate Antigens (SCA)”.

 

University of Birmingham, United Kingdom

PI - Grant Stewart

ESR 5 - Understanding how alterations in TONSL expression contribute to pancreatic cancer development

 

Technical University of Munich, Germany

PI - Tatiana Flisikowska

ESR 6 - Generate a porcine model of PDAC using oncogenic mutations of KRAS that can be activated by Cre recombination.

 

NOT AVAILABLE ANYMORE - Institute National de la Santè et de la Recherche Medicale (INSERM), France 

PI - Francois Trottein

ESR 7 - Study of receptor interactions and intracellular routing of modified nanovaccines that target DCs to improve efficacy and to maximize antigen uptake.

 

Good Biomarkers Science B.V. (GBS), The Netherlands

PI - Cornelis Kluft

ESR 8 - Identification of novel biomarkers for thrombotic risk assessment in patients with PDAC

 

Polypure A.S., Norway

PI - Erik Agner, co supervisor prof. Ferry Ossendorp (LUMC)

ESR 9 - Preparation of adjuvanted peptide-based nanovaccines for intradermal administration towards PDAC draining lymph nodes

 

Leiden University Medical Centre (LUMC), The Netherlands

PI - Dr Luis Ricondo Cruz

ESR 10 - Nanovaccine functionalization: integration of all necessary cancer vaccine components and a NIRF imaging contrast agent.

 

Staten Serums Institut (SSI), Denmark

PI - Gregers Jurgensen

ESR 11 - Characterization of tumor- and vaccine-specific immune responses in oncopigs

 

NOT AVAILABLE ANYMORE - Percuros B.V., The Netherlands

PI and coordinator Dr Alan Chan

ESR 12 - Assess the potential of different vaccine formulations in their ability to increase the co-stimulatory capacity of DCs in human, murine and porcine models.

 

NOT AVAILABLE ANYMORE Max-Planck Institute of Experimental Medicine, Germany

PI - Prof. Frauke Alves

ESR 13 - To assess the protective capacity of different nanovaccine formulations in mice and pigs using in vivo and ex vivo imaging

 

Leiden University Medical Centre (LUMC), The Netherlands

PI - Prof. Sven Mieog and Alex Vahrmeier

ESR 14 - Analysis of tissue biobank and fresh patient samples (tumour resections and whole blood) as well as biological samples from PDAC mouse models

 

NOT AVAILABLE ANYMORE - Technical University Delft, The Netherlands

PI - Marcel Reinders -

ESR 15 - CyTOF2 data analysis of the composition of immune and stromal cell compartments and the development of novel approaches for CyTOF2 data analysis of immune cell status in human subjects.

 

For more specific information about the vacancies, you can click here: PAVE Job vacancies.

If you want to apply for one of the position please read the basic eligibility criteria first and send your application to jobs@pave-cancer.eu providing all required information (incl. the ID of the position like "PAVE ESR ##" as reference).

 

Benefits

We are offering a competitive, interdisciplinary environment with a track record of intense mutual collaboration. In addition to the individual training-through-research our programme includes further elements such as workshops, summer schools, internships and secondments to the partners’ laboratories.
 

Eligibility criteria

The following eligibility rules apply for participation in a Marie Skłodowska Curie Innovative Training Network:

Applicants must be in the first 4 years after obtaining their Master´s degree and must not have resided or carried out their main activity (work, studies, etc.) in the host country for more than 12 months in the 3 years immediately before the recruitment date. In addition, local regulations of the host countries may apply.

Selection process

To apply for one of the positions please send the following information to jobs@pave-cancer.eu :

• your complete CV,

• motivation letter,

• copies of University Master certificates or equivalents and

• contact details of two references, who can provide a letter of recommendation.

Please state the vacancy reference (for example: “PAVE ESR 1”) in the subject line. It is possible to apply for more than one vacancy. After eligibility screening, your application will be forwarded to one of the appropriate consortium members for further evaluation.

Web site for additional job details

Offer Requirements

  • REQUIRED LANGUAGES
    ENGLISH: Excellent

Skills/Qualifications

There are strict eligibility requirements for the ESR PhD positions in MSCA-ITN. Please ensure that you qualify before applying, as ineligible candidates cannot be considered.

Applicants should not have resided or performed their main activity (work, studies, etc.) in the country of the host institution for more than 12 months in the 3 year period immediately prior to the start date of the PhD research.

Applicants for the ESR PhD positions should be in the first 4 years (full-time equivalent) of their research careers and not yet have been awarded a doctorate. This 4 year period is measured from the date of obtaining the degree which would formally entitle to embark on a doctorate.

 

Map Information

Work location(s)
2 position(s) available at
Max Planck Institute for Experimental Medicine
Germany
Göttingen
2 position(s) available at
Leiden University Medical Centre
Netherlands
Leiden
1 position(s) available at
Percuros B.V.
Netherlands
Leiden
1 position(s) available at
Good Biomarkers Science B.V.
Netherlands
Leiden
1 position(s) available at
Erasmus Medical Centre
Netherlands
Rotterdam
1 position(s) available at
Technical University of Munich
Germany
Munich
1 position(s) available at
Regensburg Centre of Inteventional Immunology
Germany
Regensburg
1 position(s) available at
French National Institute of Health and Medical Research
France
Lille
1 position(s) available at
University of Barcelona
Spain
Barcelona
1 position(s) available at
Statens Serum Institut
Denmark
Copenhagen
1 position(s) available at
Polypure A.S.
Norway
Oslo

EURAXESS offer ID: 450192

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.